Abstract:Abstract Background Diagnosing latent tuberculosis (TB) infection (LTBI) and active TB (ATB) is crucial for preventing disease progression and transmission. However, current diagnostic tests have limitations in terms of accuracy and sensitivity, making it challenging to diagnose these different infection states. Therefore, this study intends to develop a promising biomarker for LTBI and ATB diagnosis to overcome the limitations of the current diagnostic tests. Methods We developed a novel multiepitope-based diagnostic biomarker (MEBDB) from LTBI region of differentiation antigens using bioinformatics and immunoinformatics. Immune responses induced by MEBDM were detected using enzyme-linked immunosorbent spot and cytometric bead assays. This study was conducted from April 2022 to December 2022 in the Senior Department of Tuberculosis at the 8th Medical Center of PLA General Hospital, China. Blood samples were collected from participants with ATB, individuals with LTBI, and healthy controls (HCs). The diagnostic efficacy of MEBDB was evaluated using receiver operating characteristic curves. Results A novel MEBDB, designated as CP19128P, was generated. CP19128P comprises 19 helper T lymphocyte epitopes, 12 cytotoxic T lymphocyte epitopes, and 8 B-cell epitopes. In silico simulations demonstrated that CP19128P possesses strong affinity for Toll-like receptors and elicits robust innate and adaptive immune responses. CP19128P generated significantly higher levels of tumor necrosis factor (TNF-α), interleukin 4 (IL-4), and IL-10 in ATB patients (n = 7) and LTBI (n = 8) individuals compared with HCs (n = 62) (P < 0.001). Moreover, CP19128P-induced specific cytokines could be used to discriminate LTBI and ATB from healthy subjects with high sensitivity and specificity. Combining IL-2 with IL-4 or TNF-α could differentiate LTBI from HCs (the area under the receiver operating characteristic curve [AUC], 0.976 [95% confidence interval [CI], 0.934–1.000] or 0.986 [0.956–1.000]), whereas combining IL-4 with IL-17A or TNF-α could differentiate ATB from HCs (AUC, 0.887 [0.782–0.993] or 0.984 [0.958–1.000]). Conclusions Our study revealed that CP19128P is a potential MEBDB for the diagnosis of LTBI and ATB. Our findings suggest a promising strategy for developing novel, accurate, and sensitive diagnostic biomarkers and identifying new targets for TB diagnosis and management.

Screening of Biological Biomarker for Distinguishing Latent and Active Tuberculosis by Proteome Microarray

Novel serological biomarker panel using protein microarray can distinguish active TB from latent TB infection

Characterization of cytokine profile to distinguish latent tuberculosis from active tuberculosis and healthy controls.

Profiling the human immune response to Mycobacterium tuberculosis by human cytokine array

Genome-wide Transcriptional Profiling Identifies Potential Signatures in Discriminating Active Tuberculosis from Latent Infection

Profiling the Mrna and Mirna in Peripheral Blood Mononuclear Cells in Subjects with Active Tuberculosis

Specific Cytokines Analysis Incorporating Latency-Associated Antigens Differentiates Mycobacterium tuberculosis Infection Status: An Exploratory Study

A proteomics approach to the identification of plasma biomarkers for latent tuberculosis infection.

Screening and identification of a six-cytokine biosignature for detecting TB infection and discriminating active from latent TB

Novel Biomarkers Distinguishing Active Tuberculosis From Latent Infection Identified By Gene Expression Profile Of Peripheral Blood Mononuclear Cells

Development and Evaluation of a Promising Biomarker for Diagnosis of Latent and Active Tuberculosis Infection

Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection

Active versus latent pulmonary tuberculosis: which one is the appropriate distinguishing biomarker?

The Discovery and Identification of a Candidate Proteomic Biomarker of Active Tuberculosis

Proteomic Profiling for Plasma Biomarkers of Tuberculosis Progression

Diagnostic serum proteomic analysis in patients with active tuberculosis

Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR

Distinguish active tuberculosis with an immune-related signature and molecule subtypes: a multi-cohort analysis

Coexpression Network Analysis-Based Identification of Critical Genes Differentiating Between Latent and Active Tuberculosis.

Discovery and Identification of Serum Potential Biomarkers for Pulmonary Tuberculosis Using Itraq-Coupled Two-Dimensional Lc-Ms/Ms

Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic Biomarkers That Distinguish Active and Latent Tuberculosis